A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.
If you attended any of the events, conferences and panel discussions in the BioHealth Capital Region this year you probably would have picked up on a consistent theme. Whether it was at the ISPE Chesapeake Bay Area Chapter’s MAST Showcase, the BioHealth Capital Region Forum held at AstraZeneca in April or the more recent NCI Tech Transfer Showcase, talent and capital were hot button topics discussed intensely during the sessions, over lunch and while networking at each event.
Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.
AUTM – #Egypt tech transfer partnership and information exchange co-sponsored by the USDA continues this week with stops this week at #Maryland TEDCO and BioHealth Innovation, Inc. in the BioHealth Capital Region
Scientists are getting closer to understanding how to turn the body’s energy-storing white fat cells into energy-burning beige fat cells, opening up hopes that fat deposits could one day be deliberately manipulated to prevent obesity and related health conditions.
MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, as its Vice President, Non-Clinical and Translational Studies. In her new role, Dr. Chinnasamy will oversee all non-clinical and translational activities for MaxCyte’s CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte’s clinical-stage therapeutic development.
The Biotechnology Innovation Organization (BIO) recently released the report Transforming Ideas into Advances: Best Practices in State and Regional Bioscience Economic Development Initiatives. This biennial report provides a good summary of state initiatives serving the industry plus a discussion of new developments by state.
The 24-week, part-time program will be geared toward working professionals, who may be looking to pursue new job opportunities in tech.
I recently visited Egypt as part of a team led by the Departments of State and Agriculture, supported by the good folks at the AUTM Foundation. Egypt, like many countries, is looking at our model for integrating research universities into their economy. I was asked to speak about the Bayh-Dole Act and thought it was important to emphasize that there were many factors required beyond enacting a law to reverse an entrenched national policy.
Elon Musk grabbed a lot of attention with his July 16 announcement that his company Neuralink plans to implant electrodes into the brains of people with paralysis by next year. Their first goal is to create assistive technology to help people who can’t move or are unable to communicate.
